Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease by Nobuyuki Horita et al.
Horita et al. Respiratory Research 2014, 15:37
http://respiratory-research.com/content/15/1/37RESEARCH Open AccessEvidence suggesting that oral corticosteroids
increase mortality in stable chronic obstructive
pulmonary disease
Nobuyuki Horita1,2*, Naoki Miyazawa2, Satoshi Morita3, Ryota Kojima2, Miyo Inoue2, Yoshiaki Ishigatsubo1
and Takeshi Kaneko4Abstract
Background: Oral corticosteroids were used to control stable chronic obstructive pulmonary disease (COPD) decades
ago. However, recent guidelines do not recommend long-term oral corticosteroids (LTOC) use for stable COPD patients,
partly because it causes side-effects such as respiratory muscle deterioration and immunosuppression. Nonetheless, the
impact of LTOC on life prognosis for stable COPD patients has not been clarified.
Methods: We used the data of patients randomized to non-surgery treatment in the National Emphysema Treatment
Trial. Severe and very severe stable COPD patients who were eligible for volume reduction surgery were recruited at 17
clinical centers in the United States and randomized during 1998-2002. Patients were followed-up for at least five years.
Hazard ratios for death by LTOC were estimated by three models using Cox proportional hazard analysis and
propensity score matching.
Results: The pre-matching cohort comprised 444 patients (prescription of LTOC: 23.0%. Age: 66.6 ± 5.4 year old. Female:
35.6%. Percent predicted forced expiratory volume in one second: 27.0 ± 7.1%. Mortality during follow-up: 67.1%).
Hazard ratio using a multiple-variable Cox model in the pre-matching cohort was 1.54 (P = 0.001). Propensity score
matching was conducted with 26 parameters (C-statics: 0.73). The propensity-matched cohort comprised of 65 LTOC(+)
cases and 195 LTOC(−) cases (prescription of LTOC: 25.0%. Age: 66.5 ± 5.3 year old. Female: 35.4%. Percent predicted
forced expiratory volume in one second: 26.1 ± 6.8%. Mortality during follow-up: 71.3%). No parameters differed
between cohorts. The hazard ratio using a single-variable Cox model in the propensity-score-matched cohort was 1.50
(P = 0.013). The hazard ratio using a multiple-variable Cox model in the propensity-score-matched cohort was 1.73
(P = 0.001).
Conclusions: LTOC may increase the mortality of stable severe and very severe COPD patients.Background
In 1964, chronic obstructive pulmonary disease (COPD)
was defined as a disease condition characterized by not
reversible airflow limitation [1]. Since then, oral cortico-
steroids have often been used to control COPD [2]. In
the 1980s, administration of 7.5 − 15 mg/day of long-
term oral corticosteroids (LTOC) therapy was proved to
improve the prognosis of patients with chronic airflow* Correspondence: nobuyuki_horita@yahoo.co.jp
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unless otherwise stated.obstruction, a disease concept that partly overlaps with
bronchial asthma and COPD [3,4]. A meta − analysis in
1991 revealed that oral corticosteroids improve forced
expiratory volume in one second (FEV1) in stable COPD
patients [5]. Various studies have repeatedly confirmed
the favorable outcomes of therapy with systemic cortico-
steroids for acute exacerbation of COPD [6-10]. Guide-
lines published in 1995 thus indicated that LTOC may
have beneficial effects for stable COPD patients [11].
However, other studies indicated that LTOC is poten-
tially harmful for stable COPD patients because muscle
strength and pulmonary function deteriorate after high
dose of systemic corticosteroids [12], and because
corticosteroids cause comorbidities such as diabetes,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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prospective studies with a small number of patients re-
ported that treatment of stable COPD patients with oral
corticosteroids was not efficacious: in one study, two
weeks of treatment with 40 mg of prednisone daily did
not improve pulmonary symptoms or function [14]; in the
other, a combination of inhaled plus oral corticosteroids
for two years was not more effective than inhaled cortico-
steroids alone [15]. The current guidelines do not recom-
mend LTOC for stable COPD patients [16]. In summary,
many studies do not support the use of LTOC for stable
COPD patients, but no study has clearly demonstrated a
relationship between LTOC and life prognosis.
It is difficult to estimate how many patients worldwide
is currently taking oral corticosteroids. But data from
recently published randomized trial suggest that a con-
siderable portion of patients with COPD is still taking
oral corticosteroids. According to a report of the Under-
standing Potential Long-Term Impacts on Function with
Tiotropium trial published in 2008, 8.4% of 5992 stable
COPD cases took oral corticosteroids [17].
Given this background, it was not feasible to under-
take a randomized controlled trial that evaluated the in-
fluence of LTOC on the life prognosis of stable COPD
patients. Such a potentially harmful study is not ethicallyFigure 1 Flow chart for patient entry. NETT: National Emphysema Treatm
LTOC: long-term oral corticosteroids.allowed. Even if feasible, evaluation of life prognosis de-
mands the observation of a large number of patients for
many years. Therefore, the aim of this study was to
evaluate the life prognosis of patients treated with LTOC
using the propensity score matching method.
Methods
Study design
The data set previously collected for the National Emphy-
sema Treatment Trial (NETT) [17] was provided to us by
the National Heart, Lung, and Blood Institute. We esti-
mated the hazard ratio (HR) for death from LTOC in
three Cox proportional hazards models. In Model 1, we
calculated HR using a multiple-variable Cox model in a
pre-matching cohort. Propensity-score matching was per-
formed before the Model 2 and 3 analyses. In Model 2, we
evaluated HR using a single-variable Cox model in a pro-
pensity-score-matched cohort. In Model 3, we estimated
HR using a multiple-variable Cox model in the propen-
sity-score-matched cohort (Figure 1). Our primary end
point was death evaluated with HR by LTOC in the three
models.
The data set previously collected for the National Em-
physema Treatment Trial (NETT) was provided by the
National Heart, Lung, and Blood Institute. The currentent Trial. N: Number of patients. OC: Oral corticosteroids prescription.
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tutional Review Board. The need for informed consent
was waived for this study due to patient anonymity and
the observational nature of the study [18].
Patient selection
The major entry criteria for the NETT study were the fol-
lowing for each patient: radiographic evidence of bilateral
emphysema, % predicted FEV1 ≤ 45%, a pressure of carbon
dioxide in artery (PaCO2) ≤ 60 mmHg, a pressure of oxy-
gen in artery (PaO2) ≥ 45 mmHg, 6 −minute walking dis-
tance ≥ 140 m, participation in pulmonary rehabilitation,
not at high risk for perioperative morbidity or mortality,
suitable for lung volume reduction surgery, likely to
complete the trial. Between January 1998 and July 2002,
3777 patients were evaluated in 17 clinical centers, and
1218 patients were eligible for randomization; 608 and
610 patients were randomly allocated to the surgical and
medical cohort respectively. The criteria were described in
greater detail in the previous report [18].
We used the data set of only the medical cohort pa-
tients for our study. Among 610 patients, patients for
whom there were no data at baseline for age (N = 15),
hemoglobin (N = 1), and diffusing capacity of the lungs
for carbon monoxide (N = 3) were excluded from the
study.
We defined an LTOC(+) case as a patient for whom
oral corticosteroids were prescribed at both rando-
mization and six months after randomization. We de-
fined an LTOC(−) case likewise. Any patient who did
not satisfy LTOC(+) and LTOC(−) definitions were ex-
cluded: (i) patients for whom oral corticosteroids were
prescribed at either the randomization (N = 31) or six
months after randomization (N = 19), (ii) patients for
whom prescription of oral corticoid at six months after
randomization was not checked (N = 77), (iii) patients
who died within six months of randomization (N = 20).
Finally, 342 LTOC(−) patients and 102 LTOC(+) patients
were included in our study. These 444 patients comprised
the pre-matching cohort in our study. Propensity score
matching was performed for these 444 patients in a pre-
matching cohort and the 260 matched patients comprised
the propensity-score-matched cohort (Figure 1).
In our cohort, no death was observed in the six
months following randomization because we excluded
such patients. Therefore, our observation in this study
starts six months after randomization.
Treatments
The treatments were administered in close compliance
with the guidelines [11]. The following treatments were
administered by the primary care physician: smoking
cessation, regular use of inhaled bronchodilators, oxy-
gen therapy, influenza immunization, pneumococcalvaccination, pulmonary rehabilitation, and additional mea-
sures including oral corticosteroids. The details of the
treatment methods are described in a previous report [18].
Parameters selection and measurements
We selected the following factors for covariates: demo-
graphic factors, commonly used COPD parameters, factors
related to acute exacerbation of COPD, and treatment
(Table 1).
Among these parameters, area of emphysematous
change (%) and peak pulmonary artery pressure were not
used for multiple-variable Cox model analysis and for gen-
eration of logistic regression formula for propensity score,
as the data for some patients were not available. Forced
vital capacity (FVC) (L), FEV1 (L), and FEV1/FVC (%)
were also excluded from multiple-variable logistic regres-
sion to avoid possible multicollinearity with % predicted
FVC and/or % predicted FEV1. Other 26 parameter were
included for multi-variable logistic regression.
Spirometric data were collected after bronchodilator
use. The diffusing capacity of the lungs for carbon mon-
oxide was adjusted by hemoglobin: the diffusing capacity
of the lungs for carbon monoxide × hemoglobin /
0.0697. PaO2 and PaCO2 were measured in ambient air.
An area of emphysema was an area below −950 Houns-
field. The peak pulmonary artery pressure was measured
using an echocardiogram or right heart catheterization.
The peak pulmonary artery pressure by echocardiogram
was estimated as the “mean right atrial pressure + 4 ×
(estimated tricuspid peak systolic velocity)2. ” A recent
emergency hospital stay included both admission and
overstay in an acute care facility during the three
months preceding randomization. Death was defined as
death from all causes, not only respiratory related death.
The details of the measurement methods have been dis-
cussed in the previous report [18].
Prescription of oral corticosteroids during follow-up
We checked whether oral corticosteroids were prescribed
for patients during observation to discover how patients
“compliant” were to allocated treatment arms, LTOC(+)
or LTOC(−). All analyses evaluating death were performed
independently of oral corticosteroids prescription during
the observation, i.e. the intention-to-treat principle was
followed.
Analysis
A Wilcoxon rank sum test and a Chi − square test
(Yates’s corrected, if necessary) were used to compare
the two cohorts. A Cox proportional hazard model was
used to evaluate life prognosis. The inclusion and exclu-
sion criteria of P = 0.1 were used for stepwise variable se-
lection for a multiple-variable Cox proportional hazard
Table 1 Baseline characteristics of patients in the pre-matching cohort
All patients Comparison of LTOC(+) and (−) cohorts
LTOC(+) LTOC(−) P
N 444 102 342
Age (year) 66.5 ± 5.4 66.6 ± 5.2 66.5 ± 5.4 0.636
Sex (female) 158 (35.6%) 35 (34.3%) 123 (36.0%) 0.760
Race (not white) 24 (5.4%) 8 (7.8%) 16 (4.7%) 0.215
Annual income < 30,000$ 228 (51.4%) 53 (52%) 175 (51.2%) 0.888
% predicted FEV1 27.0 ± 7.1 25.2 ± 6.2 27.6 ± 7.2 0.004
FEV1 (L) 0.89 ± 0.25 0.73 ± 0.20 0.80 ± 0.26 0.004
FEV1/FVC (%) 31.1 ± 6.2 30.3 ± 6.2 31.4 ± 6.1 0.087
% predicted FVC 68.2 ± 15.4 65.5 ± 13.7 69.1 ± 15.7 0.051
FVC (L) 2.58 ± 0.82 2.47 ± 0.69 2.61 ± 8.3 0.200
Forced residual capacity (L) 6.00 ± 1.24 6.01 ± 1.20 6.00 ± 1.25 0.953
Hemoglobin adjusted DLCO 8.1 ± 3.1 7.6 ± 2.7 8.3 ± 3.2 0.057
Peak pulmonary artery pressure (mmHg) 33.7 ± 6.2 33.1 ± 6.1 33.8 ± 6.2 0.341
(N = 377) (N = 86) (N = 291)
Hemoglobin (g/dl) 14.4 ± 1.3 14.2 ± 1.3 14.5 ± 1.3 0.193
PaO2 (mmHg) 64.5 ± 10.0 63.4 ± 10.0 64.8 ± 10.0 0.224
PaCO2 (mmHg) 43.0 ± 5.8 43.4 ± 5.7 42.9 ± 5.8 0.326
Area of emphysema (%) 15.9 ± 10.1 14.9 ± 9.9 16.2 ± 10.2 0.299
(N = 404) (N = 96) (N = 308)
Body mass index (kg/m^2) 25.0 ± 3.5 24.4 ± 3.7 25.2 ± 3.4 0.051
Six −minute walk distance 375 ± 94 340 ± 86 386 ± 94 < 0.001
St. George Respiratory Questionnaire 53.0 ± 13.1 57.5 ± 12.4 51.7 ± 13.0 < 0.001
Shortness of Breath Questionnaire 62.2 ± 19.0 68.0 ± 17.4 60.5 ± 19.1 0.001
Beck Depression Inventory 9.1 ± 6.1 9.7 ± 5.9 9.0 ± 6.1 0.172
Recent emergency visit 77 (17.3%) 27 (26.5%) 50 (14.6%) 0.006
Recent hospital stay 56 (12.6%) 23 (22.5%) 33 (9.6%) < 0.001
LTOT during sleep 290 (65.3%) 78 (76.5%) 212 (62.0%) 0.007
LTOT on exertion 300 (67.6%) 82 (80.4%) 218 (63.7%) 0.002
Inhaled corticosteroids 316 (71.2%) 76 (74.5%) 240 (70.2%) 0.396
Long acting beta agonist 197 (44.4%) 46 (45.1%) 151 (44.2%) 0.866
Short acting beta agonist 383 (86.3%) 92 (90.2%) 291 (85.1%) 0.188
Anticholinergic agent 347 (78.2%) 80 (78.4%) 267 (78.1%) 0.938
Theophylline 181 (40.8%) 49 (48.0%) 132 (38.6%) 0.089
Diuretics 56 (12.6%) 19 (18.6%) 37 (10.8%) 0.037
LTOC: long-term oral corticosteroids.
FEV1: forced expiratory volume in one second.
FVC: forced vital capacity.
DLCO: diffusing capacity of the lung for carbon monoxide.
PaO2: pressure of oxygen in artery.
PaCO2: pressure of carbon dioxide in artery.
LTOT: long term oxygen therapy.
Peak pulmonary artery pressure and area of emphysema were not evaluated for all patients due to lack of data.
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also used for comparison of life prognosis.
Using the propensity score based on 26 parame-
ters, neighborhood propensity score matching [19] wasperformed with a maximal distance of 0.03 in propensity
score. All 444 patients in pre-matching cohort were in-
cluded for the matching process. One LTOC(+) case was
matched with three LTOC(−) controls because the pre-
Figure 3 Hazard ratio for death by long-term oral corticosteroids
(LTOC) treatment. Model 1: multiple-variable Cox model in
pre-matching cohort. Model 2: single-variable Cox model in the
propensity-score-matched cohort. Model 3: multiple-variable Cox
model in the propensity-score-matched cohort. [ ]: 95%CI.
Figure 2 Prescription of oral corticosteroids during follow-up.
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LTOC(−) patients as LTOC(+) patients. The quality of
matching was evaluated by C − statistics and by compa-
ring patient characteristics between cohorts.
Results and discussion
Pre-matching cohort
The pre-matching cohort included 444 patients, whose
mean age was 66.5 ± 5.4 years and the mean % predicted
FEV1 was 27.0 ± 7.1% at randomization. Of 444 patients,
158 (35.6%) were women, 102 (23.0%) were LTOC(+)
cases, and 342 (67.0%) were LTOC(−) cases. Some mea-
surements namely % predicted FEV1, six-minute walking
distance, St. George Respiratory Questionnaire, Shortness
of Breath Questionnaire, emergency visit, and emergency
hospital stay indicated that patients with LTOC were gen-
erally in poorer condition among LTOC(+) patients
(Table 1). During the observation, 298 patients (67.1%)
died. No patient was censored before the 1949th day. Oral
corticosteroids were prescribed for no more than 30% of
LTOC(−) patients and no less than 63% of LTOC(+) pa-
tients until 54 mo follow-up (Figure 2).
Although all patients in the cohort had substantially ad-
vanced COPD, the prescription rates of some medications,
especially long-acting beta agonist (44.4%) and theophyl-
line (40.8%), were relatively low, considering the current
guidelines that strongly recommend use of bronchodila-
tors. It is probably because the cohort was recruited since
1997 and the guideline in this era [11] did not highly ap-
preciate these medications as the current guidelines do.Model 1
The stepwise multiple-variable Cox model analysis,
which initially included LTOC and 26 other coverables
as independent variable candidates, was performed in
the pre-matching cohort. Nine independent variables
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for death from LTOC was 1.54 (95%CI: 1.19 − 2.01.
P = 0.001) (Figure 3).Table 2 Baseline characteristics of patients in the propensity-
LTOC(+
65
Age (year) 66.3 ± 5
Sex (female) 23 (35.4
Race (not white) 3 (4.6%)
Annual income < 30,000$ 36 (55.4
% predicted FEV1 26.4 ± 6
[FEV1 (L)] 0.78 ± 0
[FEV1/FVC (%)] 30.9 ± 5
% predicted FVC 66.9 ± 1
[FVC (L)] 2.53 ± 0
Forced residual capacity (L) 6.05 ± 1
Hemoglobin adjusted DLCO 7.8 ± 3.0
[Peak Pulmonary Artery Pressure (mmHg)] 33.8 ± 6
(N = 55)
Hemoglobin (g/dl) 14.4 ± 1
PaO2 (mmHg) 63.3 ± 1
PaCO2 (mmHg) 43.4 ± 5
[Area of emphysema (%)] 13.5 ± 9
(N = 60)
Body mass index (kg/m^2) 24.7 ± 3
Six −minute walk distance 362 ± 79
St. George Respiratory Questionnaire 53.8 ± 1
Shortness of Breath Questionnaire 64.0 ± 1
Beck Depression Inventory 9.0 ± 5.9
Recent emergency visit 13 (20.0
Recent hospital stay 9 (13.9%
LTOT during sleep 48 (73.8
LTOT on exertion 50 (76.9
Inhaled corticosteroids 49 (75.4
Long acting beta agonist 31 (47.7
Short acting beta agonist 57 (87.7
Anticholinergic agent 49 (75.4
Theophylline 30 (46.2
Diuretics 11 (16.9
[Parameters]: parameters that were not used in multi-variable logistic regression an
LTOC: long-term oral corticosteroids.
FEV1: forced expiratory volume in one second.
FVC: forced vital capacity.
DLCO: diffusing capacity of the lung for carbon monoxide.
PaO2: pressure of oxygen in artery.
PaCO2: pressure of carbon dioxide in artery.
LTOT: long term oxygen therapy.
Peak pulmonary artery pressure and area of emphysema were not evaluated for allPropensity-score matching
For propensity-score matching, data of all 444 patients
in pre-matching cohort were used (Figure 1). Logisticscore-matched cohort
) LTOC(−)
195 P
.0 66.6 ± 5.3 0.295
%) 69 (35.4%) 1
10 (5.1%) 0.870
%) 100 (51.3%) 0.566
.8 26.0 ± 6.6 0.461
.22 0.76 ± 0.25 0.294
.6 31.0 ± 6.0 0.746
3.8 66.1 ± 14.6 0.653
.64 2.51 ± 0.78 0.644
.22 6.05 ± 1.24 0.986
7.9 ± 3.0 0.733
.0 34.0 ± 6.6 0.782
(N = 167)
.1 14.3 ± 1.3 0.676
0.2 63.3 ± 9.8 0.989
.7 43.7 ± 6.2 0.679
.4 15.9 ± 9.8 0.085
(N = 173)
.6 24.6 ± 3.5 0.791
366 ± 90 0.689
1.8 53.9 ± 13.3 0.892
6.4 63.8 ± 18.9 0.915
9.1 ± 6.3 0.988
%) 34 (17.4%) 0.642
) 24 (12.3%) 0.747
%) 144 (73.8%) 1
%) 155 (79.5%) 0.661
%) 140 (71.8%) 0.574
%) 94 (48.2%) 0.942
%) 167 (85.6%) 0.678
%) 155 (79.5%) 0.486
%) 91 (46.7%) 0.943
%) 31 (15.9%) 0.846
alysis for Cox model and propensity score matching were shown in brackets.
patients due to lack of data.
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The body mass index, six −minute walk distance, and
St. George’s Respiratory Questionnaire were significantly
related to LTOC therapy in the logistic regression ana-
lysis for propensity matching. The mean propensity
scores among LTOC(−) and LTOC(+) patients were
0.20 ± 0.13 and 0.33 ± 0.17 respectively. The C − statistic
was 0.73. Sixty-five LTOC(+) patients were matched
with 195 LTOC(−) patients. The propensity-score-
matched cohort included 260 patients (Figure 1), whose
mean age was 66.5 ± 5.3 years and the mean % predicted
FEV1 was 26.1 ± 6.8%. Of 280 patients, 92 (35.4%) were
women (Table 2). No measurement showed a significant
difference between cohorts (Table 2). Proportions of
oral corticosteroids prescription in the propensity-score-
matched cohort were similar to those in the pre-
matched cohorts (Figure 2).Model 2
In the propensity-score-matched cohort, a single-vari-
able Cox model analysis revealed that HR for death by
LTOC was 1.50 (95%CI: 1.08 − 2.08, P = 0.013) (Figure 3).
The Kaplan-Meier curve also showed that LTOC(+) pa-
tients had poorer survival prognosis than LTOC(−) pa-
tients (P = 0.013, Log-rank test) (Figure 4).Model 3
A stepwise multiple-variable Cox model analysis which
initially included LTOC and 26 other coverables as in-
dependent variable candidates was performed in the
propensity-score-matched cohort. Nine independent va-
riables including LTOC remained in the last model. The
HR for death from LTOC was 1.73 (95%CI: 1.25 − 2.41.
P = 0.001) (Figure 3).Figure 4 Kaplan-Meier survival curve on the propensity-score-
matched cohort (Model 2).Discussion
To our knowledge, this is the first study to evaluate the
effect of oral corticosteroids on the long-term life prog-
nosis of COPD patients in solid manner. The HR for
death from LTOC estimated in the three models ranged
from 1.50 to 1.73. LTOCs were generally prescribed for
patients in a deteriorated condition (Table 1), as sug-
gested in the old guideline [11]. However, LTOC further
deteriorated the life prognosis of these patients. We still
believe that systemic corticosteroids are effective for
acute exacerbation of COPD [6-10]. However, it should
be discontinued after the acute phase. Discontinuation
of LTOC has already been proven to be safe [20]. We
strongly support the current guidelines which do not
recommend LTOC for stable COPD patients [16].
One of the most important side effect of LTOC is
respiratory muscle deterioration. Decramer observed 21
patients with COPD or asthma who were admitted to
hospitals due to exacerbations [12]. The average daily
dose of corticosteroids taken in the previous six months
was significantly related to inspiratory and expiratory
muscle strength. These relationships were independent
of the degree of bronchial obstruction estimated by %
predicted FEV1 [12]. In addition, glucocorticoids, which
are the most potent anti-inflammatory and immuno-
suppressive agents, inhibit synthesis of almost all known
cytokines and of several cell surface molecules required
for immune function [21]. It is easily anticipated that
patients who is taking oral corticosteroids have more
chance to suffer from potentially life-threatening acute
exacerbation due to the immunosuppressive states.
The results of some previous studies may appear to
conflict with the current study [3-5]. Postma observed
79 patients with chronic airflow obstruction, i.e. COPD
or asthma, whose FEV1 was less than 1000 ml for more
than 14 years [3]. The same author also observed 139
less severe patients with chronic airflow obstruction
whose FEV1 was more than 1200 ml for more 11 years
on average [4]. Both studies concluded that oral pred-
nisolone, in doses above 7.5 mg/d, may slow down the
deterioration of FEV1 [3,4]. We should interpret the
results carefully, because Postma’s study observed COPD
patients together with asthma patients. Considering
Decramer’s study [12] and Postma’s study [3,4], LTOC
may improve the respiratory function of asthma patients
but may worsen that of COPD patients.
Callahan conducted a meta-analysis to evaluate oral corti-
costeroids therapy for patients with stable COPD [5]. He
scrutinized 10 placebo controlled randomized controlled
trials and concluded that patients with stable COPD recei-
ving oral corticosteroids therapy have a 20% or greater im-
provement in baseline FEV1 approximately 10% more often
than similar patients receiving a placebo. The most im-
portant difference between Callahan’s meta-analysis and
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Among 10 randomized controlled trials in the meta-
analysis, nine observed COPD patients for 14 days or less,
and one observed COPD patients for eight weeks [5]. Oral
corticosteroids may improve FEV1 of COPD patients if
prescribed for weeks. However, it may deteriorate FEV1, if
prescribed for months or years. Another considerable limi-
tation of Callahan’s study is a publication bias, which has a
considerable impact on the result of the meta-analysis [5].
Our study had several limitations. First, it was an ob-
servational study, and not a randomized controlled trial.
Since the current guidelines [16] do not recommend ad-
ministering LTOC, a randomized controlled trial was not
thought to be a feasible design. Our study design was the
next best to a randomized controlled trial. Second, the dos-
age of oral corticosteroids in this study was not verified.
Considering that the long − term dosages in previous stu-
dies were 5 mg/d [15], 7.5 mg/d [3], and 10 − 15 mg/d [4],
a similar dosage might be prescribed for patients in our co-
hort. Third, our cohort contained only patients whose %
predicted FEV1 ≤ 45% and this study did not explain
whether LTOC worsens the life prognosis of COPD pa-
tients with % predicted FEV1 > 45. However, LTOC had
been already regarded as the last option for patients with
uncontrolled advanced COPD [11]. There was no reason to
recommend LTOC for patients with mild or moderate
COPD. Together with other inclusion and exclusion cri-
teria, the current cohort may have slight difference from
“real-world” patients. Thus, we should interpret the result
with caution. Fourth, as in other observational studies, oral
corticosteroids before observation may cause some bias.
Oral corticosteroids administered before randomization
probably deteriorate baseline characteristics of LTOC(+)
patients [12,13]. But the LTOC(+) and (−) patients in the
propensity-matched cohort were nearly equal (Table 2) by
cancelling the harm from oral corticosteroids before
randomization. The matched LTOC(+) cases would have
better condition, if they had not been treated with oral cor-
ticosteroids. Nonetheless, they had poorer life prognosis
than LTOC(−) cases. This bias made true impact of medi-
cation seem smaller. Fifth, it is not fully confirmed that
LTOC(+) patients actually took oral corticosteroids during
the entire follow-up period. The definition of LTOC(+) pa-
tients in the current study might reflect repeated short
course oral corticosteroid. In addition, patient’s adherence
to prescribed medication is not evaluated. This bias shift
the observed HR toward the null, as drop-out cases in
intentional-to-treat analysis do. Thus, oral corticosteroids
may have stronger impact on mortality than we estimated
in this study.
Conclusion
The HR for mortality from LTOC among COPD patients
with % predicted FEV1 < 45% calculated with the Coxproportional hazard model ranged from 1.50 to 1.73. We
do not recommend oral corticosteroids treatment for
patients with stable COPD.
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